Weekly Research Analysts’ Ratings Changes for Ultragenyx Pharmaceutical (RARE)

Several brokerages have updated their recommendations and price targets on shares of Ultragenyx Pharmaceutical (NASDAQ: RARE) in the last few weeks:

• 12/30/2025 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Robert W. Baird from $72.00 to $47.00. They now have an “outperform” rating on the stock.
• 12/30/2025 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Leerink Partners from $80.00 to $70.00. They now have an “outperform” rating on the stock.
• 12/30/2025 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Jefferies Financial Group Inc. from $114.00 to $63.00. They now have a “buy” rating on the stock.
• 12/30/2025 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Wells Fargo & Company from $65.00 to $45.00. They now have an “overweight” rating on the stock.
• 11/24/2025 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – Ultragenyx Pharmaceutical had its price target lowered by analysts at TD Cowen from $86.00 to $75.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Truist Financial Corporation from $100.00 to $90.00. They now have a “buy” rating on the stock.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,942 shares of the stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. This represents a 7.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 11,108 shares of company stock valued at $365,262. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.